SETTON Clara Patricia
congresos y reuniones científicas
Treatment with bone marrow pluripotential cells prevent the development of hyperalgesia in rats with sciatic nerve crush.
Huerta Grande, Córdoba,
Congreso; XXVIII Congreso Anual Sociedad Argentina de Neurociencias (SAN); 2013
Institución organizadora:
Sociedad Argentina de Investigación Neurociencias
TREATMENT WITH BONE MARROW PLURIPOTENTIAL CELLS PREVENT THE DEVELOPMENT OF HYPERALGESIA IN RATS WITH SCIATIC NERVE CRUSH Mariana Malet1,2, Vanina Usach3, Lucía Lavalle3, Patricia Setton-Avruj3 and Pablo Brumovsky1,2 1Facultad de Ciencias Biomédicas, Universidad Austral, Pilar, Buenos Aires, Argentina; 2Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET); 3Departmento de Química Biológica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, IQUIFIB- Instituto Dr Alejandro Paladini, UBA-CONICET, Buenos Aires, Argentina. We previously described, in rats undergoing sciatic nerve crush, that systemic administration of bone marrow mononuclear cells (BMMC) results in their selective accumulation in the injured site and accelerated re-myelination of the affected nerve. The aim of the present work was to evaluate if improved myelin regeneration influences pain-like behaviour. To this end Wistar male rats subjected to sciatic nerve crush, were transplanted either with BMMC or bone marrow stromal cells (BMSC). Mechanical hyperalgesia was evaluated using the Von Frey`s test at different survival times. Inmunohistochemical expression of the cyclic AMP-dependent transcription factor 3 (ATF3), typically upregulated in neurons whose axons had been injured, was evaluated in dorsal root ganglion (DRG) neurons. Animals with sciatic nerve crush exhibited mechanical hyperalgesia from day 7 up to 28 days after injury. In contrast, animals treated with BMMC or BMSC exhibited higher withdrawal thresholds than the crush group, and almost complete recovery at 49 days survival. BMSC seemed to be more efficient in preventing mechanical hyperalgesia. ATF3 was strongly upregulated in DRG neurons after sciatic nerve crush, showing a peak 14 days after injury. BMMC treatment resulted in a considerable reduction in ATF3 upregulation at 14 days. BMMC as well as BMSC treatment appears to prevent the development of hyperalgesia in animals with sciatic nerve crush, consistent with their remyelination fostering effect.